Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Pyrilutamide, a potential hair loss treatment that has been tested in Phase 2 trials and may be available for purchase through a group buy in June. It is purported to have similar effects on hair growth as Dutasteride.

The user shared progress photos of hair regrowth using copper peptides and NAD+ over five months. Another user commented on the lighting, and another praised the progress.

The user experiencing diffuse hair loss is using various treatments including RU58841, finasteride, minoxidil with tretinoin, anti-hair loss shampoo, and microneedling, and is considering adding peptides TB500, BPC157, and GHK-Cu. They have low growth hormone levels and are questioning its impact on hair loss, while another user suggests androgenic alopecia and androgens are likely the main cause of hair loss.

The conversation discusses a comprehensive hair regrowth regimen including Dutasteride, Finasteride, microneedling, RU58841, oral and topical Minoxidil, Tretinoin, and Vitamin D3. Suggestions include dropping Finasteride, increasing Dutasteride, and considering additional treatments like caffeine, melatonin, and laser therapy, while emphasizing the effectiveness of Dutasteride and Minoxidil.

The user experienced hair regrowth using a combination of Minoxidil, Finasteride, and RU58841, with Minoxidil used initially and the other treatments added later. The user believes the combination of Finasteride and RU58841 contributed to the regrowth, with RU sourced from MVsupplement.

A user (seblt) who has had side effects from finasteride, minoxidil and RU58841 but is now trying pyrilutamide as a last resort, with other users providing advice and support. They have already seen some baby hairs growing after 10-14 days of treatment and will provide updates in 1-2 weeks.

RU58841 worsened hair condition, causing thinning and unusual patterns. The user stopped using it two months ago but hasn't seen recovery, and there's speculation about androgen receptor upregulation.

Pyrilutamide phase 3 results showed little to no significant hair regrowth, but may be sufficient for maintaining current hair density. The user is unsure due to lack of recent discussions on pyrilutamide.

PP405, a promising hair loss treatment, is expected to be available by 2027, with faster trials due to its topical nature. Users are eager for its release, comparing it to existing treatments like minoxidil and finasteride, but remain cautious about its long-term effectiveness.

Some people see significant hair regrowth using treatments like finasteride and minoxidil, while others experience little to no improvement even with comprehensive treatment plans. Factors such as individual sensitivity to DHT may influence the effectiveness of these hair loss treatments.

The user has been using finasteride, minoxidil, and microneedling consistently for one month to improve hair regrowth. They also use collagen peptides, pumpkin seed oil, vitamin D, biotin, nizoral shampoo, adenosine shampoo, caffeine topical, and rosemary oil as part of their routine.

Hair follicles usually go dormant rather than die, and treatments like finasteride, minoxidil, and hormone therapy can sometimes reactivate them, though results vary. Complete regrowth is rare, especially in long-term bald areas, but some individuals see significant improvement with these treatments.

The conversation discusses the effectiveness of an eyebrow serum containing Myristoyl Pentapeptide and Biotinoyl Tripeptide for hair growth. The user seeks information on other topical products with similar peptides for hair growth.

The conversation discusses using a violet ray device for hair regrowth, citing a case where zinc ion treatments showed promising results. It also mentions similar devices like the Growcombr and niostem helmet.

Dr. Toyos is recruiting more participants for a larger trial on hair loss treatments. The discussion mentions Minoxidil, finasteride, and RU58841 as potential treatments.

Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.

People are discussing the use of an untested hair loss treatment called PP405, which is not available on the grey market. Some users are trying a mimic formulation called HP3, reporting thicker hair but no new growth yet.

The user is experiencing hair regrowth after five months on a treatment regimen including Musely's bloom+ pill (Minoxidil and Dutasteride), Nizoral, and microneedling. They are optimistic about the results and have not experienced any side effects.

Current treatments like finasteride, minoxidil, and derma rolling are considered the best for hair loss, while new treatments such as GT20029, PP405, and others are in various trial phases with results expected in the coming years. There is cautious optimism about the affordability and effectiveness of these upcoming treatments.

A user is experiencing side effects like less hard erections and sensitive nipples while on finasteride, with bloodwork showing high prolactin levels. They are seeking suggestions to address the prolactin issue.

A 43-year-old with a history of hair transplants and long-term finasteride use reports seeing hair regrowth after adding oral minoxidil, micro-needling, and resuming topical minoxidil. Users agree that the hair appears thicker and denser.

The conversation is about a person using dutasteride and minoxidil for hair loss, considering adding RU58841 and PP405 for more density. They are seeking advice on using these treatments and exploring other options like GT20029.

Male pattern baldness (MPB) may be influenced by androgen receptors in scalp hair follicles and potentially poor blood flow. Transplanted hair is not immune to DHT, and factors like inflammation and scalp tension might also contribute to hair loss.

The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.

The user has been using topical minoxidil and oral finasteride for hair regrowth, noticing some improvement and baby hairs at the hairline after four months. Suggestions include continuing the current treatment, considering microneedling, ketoconazole shampoo, vitamins, and possibly RU58841, while avoiding a hair transplant.

A user shared their hair progress after three steroid cycles, using 5% minoxidil and 100mg RU58841 daily. They are considering a hair transplant due to paranoia about shedding.

Diffuse thinning can result in varied regrowth, with some users experiencing better results at the hairline and others at the crown. Treatments mentioned include finasteride, minoxidil (oral and topical), RU58841, microneedling, and dermarolling.

User started balding at 16 and began treatment at 18, using RU58841, minoxidil, derma rolling, and peptides. After 6 months, they experienced significant hair regrowth and are happy with the results.

A 25-year-old is using a combination of oral minoxidil, finasteride, RU58841, and topical dutasteride mixed with minoxidil to combat hair loss and hopes to see regrowth. They plan to update on the effectiveness of this regimen in a few months.